Chimeric Antigen Receptor T-cells, Bispecific Antibodies and Antibody Drug Conjugates for Multiple Myeloma: An Update.

Abstract

Patients with multiple myeloma who are refractory to currently available effective therapies have short expected survival. Modalities harvesting the knowledge of the immune characteristics and microenvironment of myeloma such as chimeric antigen receptor (CAR) T-lymphocytes, bispecific antibodies and antibody-drug conjugates have shown potential in early phase trials. Based on data from phase 2 studies, idecabtagene vicleucel (ide cel), an anti-BCMA CAR T-product and belantamab mafodotin (belamaf), an antibody-drug conjugate are currently approved in the relapsed/refractory setting. Bispecific antibodies have shown promise with quick and deep responses. In this review, we summarize the available evidence on these treatments from clinical trials. This article is protected by copyright. All rights reserved.